Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| LB PHARMACEUTICALS INCLBRX · Entity 4678 | Director | June 03, 2026 | June 05, 2026 |
| Neumora Therapeutics, Inc.NMRA · Entity 6115 | Head of R&D | February 18, 2025 | February 20, 2025 |
| NovaBridge BiosciencesNBP · Entity 6324 | Director | August 22, 2026 | August 25, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
LB PHARMACEUTICALS INC
Report date June 03, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.95 · Expires 2036-06-02 | Direct | 12,500 |
Reported balance
After 2026-06-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-03 · Grant · Acquired 12,500 · Balance 12,500 F1: Includes an option award for 2,500 shares pursuant to the Issuer's non-employee director compensation policy which represents a prorated annual grant for the previous year. F2: 100% of the shares underlying the option vest on the earlier of (i) June 3, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes an option award for 2,500 shares pursuant to the Issuer's non-employee director compensation policy which represents a prorated annual grant for the previous year.
F2: 100% of the shares underlying the option vest on the earlier of (i) June 3, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date.
Neumora Therapeutics, Inc.
Report date February 18, 2025 · Filed February 20, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 309,092 |
Reported balance
After 2025-02-18 transaction · row 1
1 source rowRow 1 · 2025-02-18 · Sale · Disposed 5,614 · Balance 309,092 F1: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on June 12, 2024, which provides for the automatic sale of shares of common stock that would otherwise be issuable on each vesting date of a covered restricted stock unit in an amount necessary to satisfy the applicable withholding obligation. F2: This transaction was executed in multiple trades in prices ranging from $1.66 to $1.695, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on June 12, 2024, which provides for the automatic sale of shares of common stock that would otherwise be issuable on each vesting date of a covered restricted stock unit in an amount necessary to satisfy the applicable withholding obligation.
F2: This transaction was executed in multiple trades in prices ranging from $1.66 to $1.695, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
NovaBridge Biosciences
Report date August 22, 2026 · Filed August 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 17,218 |
Reported balance
After 2026-08-22 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-08-22 · Exercise / conversion · Acquired 17,218 · Balance 17,218 F1: The Ordinary Shares may be represented by American Depositary Shares ("ADS"). Each 10 ADSs represent 23 Ordinary Shares of the Issuer. F2: Reported securities are represented by 7,486 ADSs. F3: Each restricted stock unit ("RSU") represents a contingent right to receive one ADS. |
| Restricted Share UnitsSEC Table II · derivative / convertible security | Direct | 14,974 |
Reported balance
After 2026-08-22 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-08-22 · Exercise / conversion · Disposed 7,486 · Balance 14,974 F3: Each restricted stock unit ("RSU") represents a contingent right to receive one ADS. F4: Reported securities represent ADSs. F5: On August 22, 2025, the Reporting Person was granted 22,460 restricted share units ("RSUs"). The RSUs vested or shall vest over three years in three equal annual installments on August 22, 2026, 2027 and 2028. |
Filing footnotes · ownership attribution and instrument terms
F1: The Ordinary Shares may be represented by American Depositary Shares ("ADS"). Each 10 ADSs represent 23 Ordinary Shares of the Issuer.
F2: Reported securities are represented by 7,486 ADSs.
F3: Each restricted stock unit ("RSU") represents a contingent right to receive one ADS.
F4: Reported securities represent ADSs.
F5: On August 22, 2025, the Reporting Person was granted 22,460 restricted share units ("RSUs"). The RSUs vested or shall vest over three years in three equal annual installments on August 22, 2026, 2027 and 2028.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 22, 2026 Filed Aug 25, 2026 20:15 UTC | NovaBridge Biosciences NBP · Entity 6324 | Exercise / conversionRestricted Share Units · Derivative | 7,486 | $0.00 | $0.00 |
DisclosureSEC source: 0001992908-26-000013 · form4-08252026_040807.xml · derivative · entry 2 Lenz Robert A. · CIK 0001992908 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,974 Underlying: Ordinary Shares · 7,486 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ADS. F4 · shares: Reported securities represent ADSs. F5 · derivative.exercise_date: On August 22, 2025, the Reporting Person was granted 22,460 restricted share units ("RSUs"). The RSUs vested or shall vest over three years in three equal annual installments on August 22, 2026, 2027 and 2028. F5 · derivative.expiration_date: On August 22, 2025, the Reporting Person was granted 22,460 restricted share units ("RSUs"). The RSUs vested or shall vest over three years in three equal annual installments on August 22, 2026, 2027 and 2028. F4 · balance_after: Reported securities represent ADSs. Read SEC document |
| August 22, 2026 Filed Aug 25, 2026 20:15 UTC | NovaBridge Biosciences NBP · Entity 6324 | Exercise / conversionOrdinary Shares | 17,218 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001992908-26-000013 · form4-08252026_040807.xml · nonDerivative · entry 1 Lenz Robert A. · CIK 0001992908 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,218 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares ("ADS"). Each 10 ADSs represent 23 Ordinary Shares of the Issuer. F2 · shares: Reported securities are represented by 7,486 ADSs. F3 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one ADS. F2 · balance_after: Reported securities are represented by 7,486 ADSs. Read SEC document |
| June 03, 2026 Filed Jun 5, 2026 21:26 UTC | LB PHARMACEUTICALS INC LBRX · Entity 4678 | GrantStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $27.95 | $0.00 |
DisclosureSEC source: 0001992908-26-000011 · form4-06052026_090641.xml · derivative · entry 1 Lenz Robert A. · CIK 0001992908 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2036-06-02 F1 · shares: Includes an option award for 2,500 shares pursuant to the Issuer's non-employee director compensation policy which represents a prorated annual grant for the previous year. F2 · derivative.exercise_date: 100% of the shares underlying the option vest on the earlier of (i) June 3, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| March 06, 2026 Filed Mar 10, 2026 20:19 UTC | LB PHARMACEUTICALS INC LBRX · Entity 4678 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $23.78 | $0.00 |
DisclosureSEC source: 0001992908-26-000007 · form4-03102026_080331.xml · derivative · entry 1 Lenz Robert A. · CIK 0001992908 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2036-03-05 F1 · derivative.exercise_date: The shares subject to the option award shall vest in three (3) equal annual installments on March 6, 2027, March 6, 2028 and March 6, 2029, subject to the Reporting Person's continuous service through each such date. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 22:12 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | SaleCommon Stock | 5,614 | $1.67 | $9,383.24 |
DisclosureSEC source: 0001610717-25-000028 · form4.xml · nonDerivative · entry 1 Lenz Robert A. · CIK 0001992908 · Head of R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 309,092 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on June 12, 2024, which provides for the automatic sale of shares of common stock that would otherwise be issuable on each vesting date of a covered restricted stock unit in an amount necessary to satisfy the applicable withholding obligation. F2 · price: This transaction was executed in multiple trades in prices ranging from $1.66 to $1.695, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 21:30 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | GrantStock Option (Right to Buy) · Derivative | 100,000 | Not disclosed Strike: $1.69 | Not disclosed |
DisclosureSEC source: 0000950170-25-022322 · ownership.xml · derivative · entry 4 Lenz Robert A. · CIK 0001992908 · Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2034-02-14 F4 · derivative.exercise_price: Effective February 13, 2025, subject to and contingent on the approval by the Issuer's stockholders, the Board approved an option repricing with an exercise price of $1.69 per share (the "Repricing") of the outstanding stock options held by members of the Board, certain employees and other service providers, provided that if the requisite approval of the Issuer's stockholders is not obtained, the Repricing will be void and the terms of each repriced option shall continue to be subject to its original terms and conditions, including, without limitation, the per share exercise price. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026. F2 · price: On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged. F3 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from February 14, 2024 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 21:30 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | GrantStock Option (Right to Buy) · Derivative | 502,934 | Not disclosed Strike: $1.69 | Not disclosed |
DisclosureSEC source: 0000950170-25-022322 · ownership.xml · derivative · entry 3 Lenz Robert A. · CIK 0001992908 · Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 502,934 Underlying: Common Stock · 502,934 shares Expires 2033-09-14 F4 · derivative.exercise_price: Effective February 13, 2025, subject to and contingent on the approval by the Issuer's stockholders, the Board approved an option repricing with an exercise price of $1.69 per share (the "Repricing") of the outstanding stock options held by members of the Board, certain employees and other service providers, provided that if the requisite approval of the Issuer's stockholders is not obtained, the Repricing will be void and the terms of each repriced option shall continue to be subject to its original terms and conditions, including, without limitation, the per share exercise price. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026. F2 · price: On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged. F1 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from September 11, 2023 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 21:30 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | Disposition to issuerStock Option (Right to Buy) · Derivative | 100,000 | Not disclosed Strike: $18.07 | Not disclosed |
DisclosureSEC source: 0000950170-25-022322 · ownership.xml · derivative · entry 2 Lenz Robert A. · CIK 0001992908 · Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2034-02-14 F2 · price: On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged. F3 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from February 14, 2024 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 21:30 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | Disposition to issuerStock Option (Right to Buy) · Derivative | 502,934 | Not disclosed Strike: $17.00 | Not disclosed |
DisclosureSEC source: 0000950170-25-022322 · ownership.xml · derivative · entry 1 Lenz Robert A. · CIK 0001992908 · Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 502,934 shares Expires 2033-09-14 F2 · price: On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged. F1 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from September 11, 2023 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| October 10, 2024 Filed Oct 11, 2024 20:10 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | SaleCommon Stock | 8,260 | $15.09 | $124,602.93 |
DisclosureSEC source: 0001610717-24-000505 · form4.xml · nonDerivative · entry 2 Lenz Robert A. · CIK 0001992908 · Head of R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 314,706 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on June 12, 2024. F3 · price: This transaction was executed in multiple trades in prices ranging from $15.00 to 15.2435, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| October 09, 2024 Filed Oct 11, 2024 20:10 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | SaleCommon Stock | 5,563 | $15.01 | $83,507.31 |
DisclosureSEC source: 0001610717-24-000505 · form4.xml · nonDerivative · entry 1 Lenz Robert A. · CIK 0001992908 · Head of R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 322,966 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on June 12, 2024. F2 · price: This transaction was executed in multiple trades in prices ranging from $15.00 to $15.065, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| September 18, 2024 Filed Sep 19, 2024 20:35 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | SaleCommon Stock | 10,676 | $12.09 | $129,090.99 |
DisclosureSEC source: 0001610717-24-000490 · form4.xml · nonDerivative · entry 2 Lenz Robert A. · CIK 0001992908 · Head of R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 328,529 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on June 12, 2024. F3 · price: This transaction was executed in multiple trades in prices ranging from $12.00 to $12.18, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| September 17, 2024 Filed Sep 19, 2024 20:35 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | SaleCommon Stock | 30,788 | $11.81 | $363,735.59 |
DisclosureSEC source: 0001610717-24-000490 · form4.xml · nonDerivative · entry 1 Lenz Robert A. · CIK 0001992908 · Head of R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 339,205 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on June 12, 2024. F2 · price: This transaction was executed in multiple trades in prices ranging from $11.5985 to $12.08, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| September 12, 2024 Filed Sep 16, 2024 20:05 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | SaleCommon Stock | 32,948 | $11.43 | $376,664.83 |
DisclosureSEC source: 0001610717-24-000478 · form4.xml · nonDerivative · entry 1 Lenz Robert A. · CIK 0001992908 · Head of R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 369,993 F1 · kind: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on June 12, 2024 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units. F2 · price: This transaction was executed in multiple trades in prices ranging from $11.22 to $11.6050, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 21:13 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $18.07 | $0.00 |
DisclosureSEC source: 0001610717-24-000063 · form4.xml · derivative · entry 2 Lenz Robert A. · CIK 0001992908 · Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2034-02-13 F2 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from February 14, 2024 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 21:13 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-24-000063 · form4.xml · nonDerivative · entry 1 Lenz Robert A. · CIK 0001992908 · Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 402,941 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 25% of the RSUs vest annually measured from February 14, 2024 (the "Vesting Commencement Date"), such that 100% of the RSUs will be fully vested on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| September 14, 2023 Filed Sep 18, 2023 21:58 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | GrantStock Option (Right to Buy) · Derivative | 502,934 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001610717-23-000286 · form4.xml · derivative · entry 2 Lenz Robert A. · CIK 0001992908 · Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 502,934 Underlying: Common Stock · 502,934 shares Expires 2033-09-13 F2 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from September 11, 2023 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| September 14, 2023 Filed Sep 18, 2023 21:58 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | GrantCommon Stock | 352,941 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-23-000286 · form4.xml · nonDerivative · entry 1 Lenz Robert A. · CIK 0001992908 · Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 352,941 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/4th of the RSUs vest annually on September 11 of each year, with the first 1/4th vesting on September 11, 2024. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.